Home > Publications Database > A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer's disease. > print

001     278568
005     20250601001318.0
024 7 _ |a 10.1038/s41746-025-01583-5
|2 doi
024 7 _ |a pmid:40348870
|2 pmid
024 7 _ |a pmc:PMC12065824
|2 pmc
024 7 _ |a altmetric:177141712
|2 altmetric
037 _ _ |a DZNE-2025-00601
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Polk, Sarah E
|0 P:(DE-2719)9002772
|b 0
|e First author
|u dzne
245 _ _ |a A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer's disease.
260 _ _ |a [Basingstoke]
|c 2025
|b Macmillan Publishers Limited
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1748427700_12512
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Characterizing subtle cognitive changes in preclinical Alzheimer's disease (AD) is difficult using traditional neuropsychological assessments. Remote and unsupervised digital assessments can improve scalability, measurement reliability, and ecological validity, enabling the capture of subtle changes. We evaluate such tools for use in preclinical AD, or cognitively unimpaired individuals with abnormal levels of AD pathology. We screened 1904 reports for studies remotely assessing cognition in preclinical AD samples. Twenty-three tools were identified, and their usability, reliability, and validity, including construct and criterion validity based on in-person neuropsychological and Aβ/tau measures, was reported. We present a necessary update to a rapidly evolving field, following our previous review (Öhman et al., 2021) and address open questions of feasibility and reliability of remote testing in older adults. Future applications of such tools are discussed, including longitudinal monitoring of cognition, scalable case finding, and individualized prognostics in both clinical trials and healthcare contexts.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
700 1 _ |a Öhman, Fredrik
|b 1
700 1 _ |a Hassenstab, Jason
|b 2
700 1 _ |a König, Alexandra
|b 3
700 1 _ |a Papp, Kathryn V
|b 4
700 1 _ |a Schöll, Michael
|b 5
700 1 _ |a Berron, David
|0 P:(DE-2719)2812972
|b 6
|e Last author
|u dzne
773 _ _ |a 10.1038/s41746-025-01583-5
|g Vol. 8, no. 1, p. 266
|0 PERI:(DE-600)2925182-5
|n 1
|p 266
|t npj digital medicine
|v 8
|y 2025
|x 2398-6352
856 4 _ |u https://pub.dzne.de/record/278568/files/DZNE-2025-00601%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/278568/files/DZNE-2025-00601.pdf
856 4 _ |u https://pub.dzne.de/record/278568/files/DZNE-2025-00601%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/278568/files/DZNE-2025-00601%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/278568/files/DZNE-2025-00601%20SUP.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/278568/files/DZNE-2025-00601.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:278568
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002772
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2812972
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-01
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b NPJ DIGIT MED : 2022
|d 2025-01-01
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NPJ DIGIT MED : 2022
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:42:56Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:42:56Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-01
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-01
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-04-10T15:42:56Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-01
920 1 _ |0 I:(DE-2719)5000070
|k AG Berron
|l Clinical Cognitive Neuroscience
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000070
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21